Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
TARA Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TARA Stock 12 Month Forecast
Average Price Target
$25.00
▲(338.60% Upside)
| Highest Price Target$30.00 | Average Price Target$25.00 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$26
Buy
356.14%
Upside
Reiterated
12/03/25
Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positionings: This morning, TARA hosted a webinar covering updated Ph 2 ADVANCED-2 data covering TARA-002 in BCG-naive CIS (± Ta/T1) NMIBC, and highlighted wri en feedback from FDA interacons regarding registraonal de velopment paths. Key clinical updates since the prior July 2025 data cut (note on SUO abstract) include 72% anyme CR r ate in N=21/29 paen ts, with 69% CR rate at 6-mo (N=18/26) and 50% CR rate at 12-mo (N=7/14) as of a Nov 7th, 2025 cutoff. The drug works in BCG-naive NMIBC (unsurprising but nevertheless posiv e) and more importantly, FDA is allowing a registraonal pa th that avoids BCG, potenally includes a ph ysician's choice intravesical chemo comparator arm, likely enrolls <500 pts and has a 6-month CR rate as primary endpoint (not me-t o-event).
H.C. Wainwright
$23
Buy
303.51%
Upside
Reiterated
12/03/25
Protara's TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy RatingValuation and risks to reaching our price target. Our price target of $23 is based on an equally weighted composite of: (a) $20.89/share, as a 35x multiple of taxed and diluted $1.66 discounted back to and (b) an NPV of $24.3/share (discounted cash flow analysis using a 12.0% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).
TD Cowen
$50→$30
Buy
426.32%
Upside
Reiterated
12/03/25
JonesTrading
$21
Buy
268.42%
Upside
Reiterated
12/03/25
Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug TrialWe note that CG Oncology will also present initial data with cretostimogene in the BCG-Naive NMIBC setting on December 5th, 2025 at 12:30PM ET. Key takeaways from the update: FDA alignment. The FDA will allow Protara to run a pivotal trial with TARA-002 against physician's choice of intravesical-delivered chemotherapy, and not BCG.
Oppenheimer
$25
Buy
338.60%
Upside
Reiterated
11/20/25
Scotiabank
$12
Buy
110.53%
Upside
Reiterated
05/09/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$26
Buy
356.14%
Upside
Reiterated
12/03/25
Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positionings: This morning, TARA hosted a webinar covering updated Ph 2 ADVANCED-2 data covering TARA-002 in BCG-naive CIS (± Ta/T1) NMIBC, and highlighted wri en feedback from FDA interacons regarding registraonal de velopment paths. Key clinical updates since the prior July 2025 data cut (note on SUO abstract) include 72% anyme CR r ate in N=21/29 paen ts, with 69% CR rate at 6-mo (N=18/26) and 50% CR rate at 12-mo (N=7/14) as of a Nov 7th, 2025 cutoff. The drug works in BCG-naive NMIBC (unsurprising but nevertheless posiv e) and more importantly, FDA is allowing a registraonal pa th that avoids BCG, potenally includes a ph ysician's choice intravesical chemo comparator arm, likely enrolls <500 pts and has a 6-month CR rate as primary endpoint (not me-t o-event).
H.C. Wainwright
$23
Buy
303.51%
Upside
Reiterated
12/03/25
Protara's TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy RatingValuation and risks to reaching our price target. Our price target of $23 is based on an equally weighted composite of: (a) $20.89/share, as a 35x multiple of taxed and diluted $1.66 discounted back to and (b) an NPV of $24.3/share (discounted cash flow analysis using a 12.0% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).
TD Cowen
$50→$30
Buy
426.32%
Upside
Reiterated
12/03/25
JonesTrading
$21
Buy
268.42%
Upside
Reiterated
12/03/25
Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug TrialWe note that CG Oncology will also present initial data with cretostimogene in the BCG-Naive NMIBC setting on December 5th, 2025 at 12:30PM ET. Key takeaways from the update: FDA alignment. The FDA will allow Protara to run a pivotal trial with TARA-002 against physician's choice of intravesical-delivered chemotherapy, and not BCG.
Oppenheimer
$25
Buy
338.60%
Upside
Reiterated
11/20/25
Scotiabank
$12
Buy
110.53%
Upside
Reiterated
05/09/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/14/25
Best Analysts Covering Protara Therapeutics
1 Month
xxx
Success Rate
3/7 ratings generated profit
Average Return
+10.30%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +10.30% per trade.
3 Months
xxx
Success Rate
4/7 ratings generated profit
Average Return
+25.63%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +25.63% per trade.
1 Year
Success Rate
6/7 ratings generated profit
Average Return
+48.11%
reiterated a buy rating 12 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +48.11% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
Average Return
+41.38%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +41.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TARA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
11
10
13
16
17
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
13
16
17
Each month's total comprises the sum of three months' worth of ratings.
TARA Financial Forecast
TARA Stock Forecast FAQ
What is TARA’s average 12-month price target, according to analysts?
Based on analyst ratings, Protara Therapeutics’s 12-month average price target is 25.00.
What is TARA’s upside potential, based on the analysts’ average price target?
Protara Therapeutics has 338.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TARA a Buy, Sell or Hold?
Protara Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Protara Therapeutics’s price target?
The average price target for Protara Therapeutics is 25.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 338.60% Increase from the current price of $5.7.
The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 338.60% Increase from the current price of $5.7.
What do analysts say about Protara Therapeutics?
Protara Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of TARA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.